Quantinno Capital Management LP Has $2.95 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN

Quantinno Capital Management LP lifted its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 41.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 52,147 shares of the biotechnology company’s stock after purchasing an additional 15,225 shares during the quarter. Quantinno Capital Management LP’s holdings in BioMarin Pharmaceutical were worth $2,946,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. SummitTX Capital L.P. boosted its position in BioMarin Pharmaceutical by 129.7% in the first quarter. SummitTX Capital L.P. now owns 90,632 shares of the biotechnology company’s stock valued at $5,120,000 after buying an additional 51,180 shares in the last quarter. Rice Hall James & Associates LLC increased its holdings in shares of BioMarin Pharmaceutical by 4.5% during the first quarter. Rice Hall James & Associates LLC now owns 104,659 shares of the biotechnology company’s stock worth $5,912,000 after buying an additional 4,489 shares in the last quarter. Waverly Advisors LLC raised its stake in shares of BioMarin Pharmaceutical by 32.0% in the first quarter. Waverly Advisors LLC now owns 6,676 shares of the biotechnology company’s stock valued at $377,000 after acquiring an additional 1,617 shares during the last quarter. Inceptionr LLC boosted its holdings in shares of BioMarin Pharmaceutical by 73.8% in the 1st quarter. Inceptionr LLC now owns 30,726 shares of the biotechnology company’s stock worth $1,736,000 after acquiring an additional 13,048 shares in the last quarter. Finally, Systematic Financial Management LP boosted its holdings in shares of BioMarin Pharmaceutical by 0.4% in the 1st quarter. Systematic Financial Management LP now owns 255,354 shares of the biotechnology company’s stock worth $14,425,000 after acquiring an additional 954 shares in the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

BioMarin Pharmaceutical News Summary

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Q2 results exceeded expectations. BioMarin reported adjusted earnings of $1.20 per share versus the $0.95–$0.96 analyst consensus, while revenue rose 20% year over year to approximately $990 million, ahead of estimates near $932 million. BioMarin Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its 2026 outlook. Full-year adjusted EPS guidance increased to $4.90-$5.10 from a prior level below that range and above the roughly $4.80 consensus. Revenue guidance was set around $3.9 billion. Stronger-than-expected VOXZOGO sales and continued momentum in key therapies supported the revision. BioMarin Reports Second Quarter 2026 Results
• Positive Sentiment: Amicus additions could improve long-term growth. BioMarin said the addition of GALAFOLD and POMBILITI plus OPFOLDA, along with cost synergies, should accelerate revenue growth, earnings accretion, operating-margin expansion and cash flow through the mid-2030s. BioMarin Lifts 2026 Outlook
• Positive Sentiment: Morgan Stanley raised its price target to $124 from $119 and maintained an Overweight rating, signaling substantial potential upside in its valuation view.
• Neutral Sentiment: HC Wainwright increased its target to $60 from $50 but retained a Neutral rating, indicating more cautious expectations than Morgan Stanley.
• Negative Sentiment: BioMarin discontinued a $270 million rare-disease asset after the treatment missed its Phase 3 endpoint. The setback removes a potential growth opportunity and highlights clinical-development risk. BioMarin Axes Rare-Disease Asset

BioMarin Pharmaceutical Stock Performance

BMRN stock opened at $63.81 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 5.81 and a quick ratio of 4.20. The company has a 50 day moving average price of $58.19 and a 200 day moving average price of $57.06. BioMarin Pharmaceutical Inc. has a fifty-two week low of $49.26 and a fifty-two week high of $66.28. The stock has a market capitalization of $12.33 billion, a PE ratio of 172.46, a price-to-earnings-growth ratio of 0.49 and a beta of 0.24.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.25. The firm had revenue of $989.71 million for the quarter, compared to the consensus estimate of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.36% and a net margin of 2.14%.The business’s revenue for the quarter was up 20.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Analysts forecast that BioMarin Pharmaceutical Inc. will post 4.22 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on BMRN. UBS Group reaffirmed a “neutral” rating on shares of BioMarin Pharmaceutical in a report on Tuesday, July 14th. HC Wainwright increased their target price on BioMarin Pharmaceutical from $50.00 to $60.00 and gave the stock a “neutral” rating in a report on Friday. Weiss Ratings upgraded BioMarin Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, June 26th. Oppenheimer raised their target price on BioMarin Pharmaceutical from $95.00 to $97.00 and gave the company an “outperform” rating in a research note on Friday. Finally, Canaccord Genuity Group cut their price target on BioMarin Pharmaceutical from $116.00 to $111.00 and set a “buy” rating for the company in a report on Friday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $87.86.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.